Biohaven End Period Cash Flow vs Free Cash Flow Per Share Analysis
| BHVN Stock | USD 42.81 0.22 0.52% |
Biohaven Pharmaceutical financial indicator trend analysis is way more than just evaluating Biohaven Pharmaceutical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biohaven Pharmaceutical is a good investment. Please check the relationship between Biohaven Pharmaceutical End Period Cash Flow and its Free Cash Flow Per Share accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
End Period Cash Flow vs Free Cash Flow Per Share
End Period Cash Flow vs Free Cash Flow Per Share Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biohaven Pharmaceutical End Period Cash Flow account and Free Cash Flow Per Share. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Biohaven Pharmaceutical's End Period Cash Flow and Free Cash Flow Per Share is -0.2. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Free Cash Flow Per Share in the same time period over historical financial statements of Biohaven Pharmaceutical Holding, assuming nothing else is changed. The correlation between historical values of Biohaven Pharmaceutical's End Period Cash Flow and Free Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Biohaven Pharmaceutical Holding are associated (or correlated) with its Free Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Per Share has no effect on the direction of End Period Cash Flow i.e., Biohaven Pharmaceutical's End Period Cash Flow and Free Cash Flow Per Share go up and down completely randomly.
Correlation Coefficient | -0.2 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
End Period Cash Flow
Free Cash Flow Per Share
The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.Most indicators from Biohaven Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biohaven Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. At this time, Biohaven Pharmaceutical's Selling General Administrative is very stable compared to the past year. As of the 11th of December 2024, Enterprise Value is likely to grow to about 3 B, though Tax Provision is likely to grow to (1.3 M).
| 2022 | 2023 | 2024 (projected) | Interest Expense | 1.4M | 1.2M | 1.2M | Depreciation And Amortization | 1.4M | 6.9M | 7.3M |
Biohaven Pharmaceutical fundamental ratios Correlations
Click cells to compare fundamentals
Biohaven Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biohaven Pharmaceutical fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 344.3M | 111.5M | 142.1M | 661.8M | 513.2M | 347.2M | |
| Other Current Liab | 52.1M | 27.1M | 37.2M | 38.1M | 36.5M | 32.1M | |
| Total Current Liabilities | 66.2M | 29.9M | 41.9M | 90.0M | 55.4M | 49.1M | |
| Total Stockholder Equity | (7.4M) | 16.8M | 34.7M | 538.8M | 428.0M | 449.4M | |
| Property Plant And Equipment Net | 8.2M | 13.6M | 18.2M | 52.4M | 48.6M | 51.0M | |
| Net Debt | (316.7M) | 185.0M | 550.7M | (174.3M) | (217.5M) | (206.6M) | |
| Retained Earnings | (972.4M) | (1.7B) | (2.6B) | (91.1M) | (499.3M) | (524.3M) | |
| Accounts Payable | 14.1M | 2.8M | 4.8M | 10.7M | 15.6M | 10.0M | |
| Cash | 316.7M | 82.5M | 76.1M | 204.9M | 248.4M | 151.3M | |
| Non Current Assets Total | 16.0M | 21.7M | 47.2M | 74.8M | 70.8M | 40.6M | |
| Non Currrent Assets Other | 7.8M | 1.0M | 3.2M | 2.6M | 2.4M | 4.2M | |
| Cash And Short Term Investments | 316.7M | 82.5M | 76.1M | 465.3M | 381.8M | 270.0M | |
| Liabilities And Stockholders Equity | 344.3M | 111.5M | 142.1M | 661.8M | 513.2M | 347.2M | |
| Non Current Liabilities Total | 285.5M | 4.8M | 5.4M | 33.0M | 29.8M | 55.3M | |
| Other Current Assets | 11.6M | 10K | 2.1M | 75.5M | 47.4M | 49.7M | |
| Other Stockholder Equity | 83.5M | 98.9M | 169.7M | 13.9M | 39.8M | 73.8M | |
| Total Liab | 351.7M | 34.7M | 47.4M | 123.0M | 85.2M | 91.0M | |
| Total Current Assets | 328.3M | 89.8M | 94.8M | 587.0M | 442.4M | 306.6M | |
| Common Stock | 881.4M | 1.2B | 1.7B | 615.7M | 887.5M | 970.6M |
Pair Trading with Biohaven Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biohaven Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biohaven Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Biohaven Stock
| 0.54 | PTN | Palatin Technologies | PairCorr |
| 0.39 | DYAI | Dyadic International | PairCorr |
| 0.34 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
The ability to find closely correlated positions to Biohaven Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biohaven Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biohaven Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biohaven Pharmaceutical Holding to buy it.
The correlation of Biohaven Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biohaven Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biohaven Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biohaven Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.37) | Return On Assets (1.19) | Return On Equity (2.65) |
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.